Linnaeus Therapeutics, Inc.
Clinical trials sponsored by Linnaeus Therapeutics, Inc., explained in plain language.
-
New pill aims to shrink tough cancers when other drugs fail
Disease control Recruiting nowThis study is testing a new oral drug called LNS8801 to see if it is safe and can help control advanced solid tumors. It is for adults whose cancer has progressed despite standard treatments. The drug will be tested both by itself and in combination with an existing immunotherapy…
Phase: PHASE1, PHASE2 • Sponsor: Linnaeus Therapeutics, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for Tough-to-Treat skin cancer
Disease control Recruiting nowThis study is testing a new oral drug, LNS8801, for people with advanced melanoma that has spread and no longer responds to standard immunotherapies. Researchers want to see if LNS8801, taken alone or combined with the drug pembrolizumab, can stop or slow cancer growth better tha…
Phase: PHASE2, PHASE3 • Sponsor: Linnaeus Therapeutics, Inc. • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC